LATEST RUGBY WORLD MAGAZINE SUBSCRIPTION DEALS Playmaker: Matthieu Jalibert was at ten for France (Getty Images) Can’t get to the shops? You can download the digital edition of Rugby World straight to your tablet or subscribe to the print edition to get the magazine delivered to your door.Follow Rugby World on Facebook, Instagram and Twitter. This show of composure was impressive from the fly-half, brought in to start with Romain Ntamack out.As you will see below, a drop-goal is all too rare in the Test game these days (though it is worth noting that Moises Duque slotted one for Brazil against Uruguay recently). France fans will be delighted with the maturity shown by their playmakers. In fact, while there was a lot of fanfare about the most recent Six Nations player of the tourament, Antoine Dupont, in this one he was happy to draw defenders onto him and let others exploit the space. Matthieu Jalibert scores rare drop-goal for France in victory over ScotlandFrance exorcised the demons of their Six Nations loss at Murrayfield by defeating Scotland 22-15 in the Autumn Nations Cup.The visitors had the edge through forward grunt, set-piece power and one breakthrough try for Virimi Vakatawa on the other side of half-time. But Scotland still managed to keep in touch and could even have fought back in the end for a draw, had a late penalty kick from captain Stuart Hogg gone into touch rather than heading into the dead-ball area.French discipline was not where they will have wanted it either. However, a win’s a win for all that.And we saw a rare drop-goal for France! Check out this decisive move to get the telling try early in the second half. The fly-half slotted a three-pointer against Scotland France are now in the box seat in Pool B of the Autumn Nations Cup, and face Italy in France next week to end the pool stage. Win that and they are in line for a final with the top side in Pool A – a trip to Twickenham would be a gargantuan challenge and one to excite spectators.As for Scotland, they already know they have a 28-0 result, with Fiji unable to compete due to a Coronavirus outbreak in their ranks.
Director of Administration & Finance Atlanta, GA Submit an Event Listing AddThis Sharing ButtonsShare to PrintFriendlyPrintFriendlyShare to FacebookFacebookShare to TwitterTwitterShare to EmailEmailShare to MoreAddThis Director of Music Morristown, NJ Bishop Diocesan Springfield, IL The Church Investment Group Commends the Taskforce on the Theology of Money on its report, The Theology of Money and Investing as Doing Theology Church Investment Group Join the Episcopal Diocese of Texas in Celebrating the Pauli Murray Feast Online Worship Service June 27 Bishop Elections Episcopal Migration Ministries’ Virtual Prayer Vigil for World Refugee Day Facebook Live Prayer Vigil June 20 @ 7 p.m. ET Assistant/Associate Rector Washington, DC Press Release Service Posted Oct 24, 2019 Rector Bath, NC Rector Collierville, TN Missioner for Disaster Resilience Sacramento, CA Ya no son extranjeros: Un diálogo acerca de inmigración Una conversación de Zoom June 22 @ 7 p.m. ET Rector and Chaplain Eugene, OR Submit a Press Release Rector Knoxville, TN New Berrigan Book With Episcopal Roots Cascade Books Curate (Associate & Priest-in-Charge) Traverse City, MI [Diocese of Missouri] The Episcopal Diocese of Missouri is pleased to announce a slate of three nominees to become its 11th bishop:The Rev. Stacey Fussell, rector at Episcopal Church of the Ascension in Bradford, PennsylvaniaThe Rev. Deon K. Johnson, rector at St. Paul’s Episcopal Church in Brighton, MichiganThe Rev. George D. Smith, rector at St. Mark’s Episcopal Church in Glen Ellyn, IllinoisA committee made up of lay and clergy members from throughout the diocese conducted a search and discernment process lasting nearly a year. Their slate was presented and was approved by the Standing Committee on Sept. 26.The nominees are scheduled to visit the diocese Nov. 4-7 for a series of four “walkabouts.” These meet-and-greet sessions will give members an opportunity to ask questions of the nominees, as well as provide time for the candidates to learn more about the diocese.The bishop election will be held Nov. 23 at Christ Church Cathedral in St. Louis. The new bishop will be consecrated on April 25, 2020.The Rt. Rev. George Wayne Smith, the 10th bishop of Missouri, announced his retirement last year. The diocese will celebrate his leadership and ministry at a special event March 28, 2020.To learn more about the diocese, the bishop nominees and the bishop election, visit the diocesan website at diocesemo.org. Associate Priest for Pastoral Care New York, NY Featured Events Rector Hopkinsville, KY Featured Jobs & Calls An Evening with Presiding Bishop Curry and Iconographer Kelly Latimore Episcopal Migration Ministries via Zoom June 23 @ 6 p.m. ET Rector (FT or PT) Indian River, MI In-person Retreat: Thanksgiving Trinity Retreat Center (West Cornwall, CT) Nov. 24-28 Associate Rector for Family Ministries Anchorage, AK Seminary of the Southwest announces appointment of two new full time faculty members Seminary of the Southwest Rector/Priest in Charge (PT) Lisbon, ME This Summer’s Anti-Racism Training Online Course (Diocese of New Jersey) June 18-July 16 Rector Albany, NY Youth Minister Lorton, VA Course Director Jerusalem, Israel Assistant/Associate Priest Scottsdale, AZ Cathedral Dean Boise, ID Rector Tampa, FL Curate Diocese of Nebraska Episcopal Charities of the Diocese of New York Hires Reverend Kevin W. VanHook, II as Executive Director Episcopal Charities of the Diocese of New York Rector Shreveport, LA The Church Pension Fund Invests $20 Million in Impact Investment Fund Designed to Preserve Workforce Housing Communities Nationwide Church Pension Group Priest-in-Charge Lebanon, OH Rector Martinsville, VA Rector Washington, DC TryTank Experimental Lab and York St. John University of England Launch Survey to Study the Impact of Covid-19 on the Episcopal Church TryTank Experimental Lab Canon for Family Ministry Jackson, MS Tags Associate Rector Columbus, GA Inaugural Diocesan Feast Day Celebrating Juneteenth San Francisco, CA (and livestream) June 19 @ 2 p.m. PT Remember Holy Land Christians on Jerusalem Sunday, June 20 American Friends of the Episcopal Diocese of Jerusalem Family Ministry Coordinator Baton Rouge, LA Rector Belleville, IL Submit a Job Listing Virtual Celebration of the Jerusalem Princess Basma Center Zoom Conversation June 19 @ 12 p.m. ET Diocese of Missouri prepares for bishop election Rector Smithfield, NC Priest Associate or Director of Adult Ministries Greenville, SC Rector Pittsburgh, PA Assistant/Associate Rector Morristown, NJ
ArchDaily “COPY” Photographs: James Hung Manufacturers Brands with products used in this architecture project Australia Ocean Shores House / Atelier Chen Hung Manufacturers: GRAPHISOFT, Boral, Cemintel, Laminex, AWS, Ampelite CopyHouses•Ocean Shores, Australia Photographs ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/933634/ocean-shores-house-atelier-chen-hung Clipboard Save this picture!© James Hung+ 17Curated by Paula Pintos Share Landscape: 2015 Year: Houses Builder: Ocean Shores House / Atelier Chen HungSave this projectSaveOcean Shores House / Atelier Chen Hung SJ Reynolds Constructions “COPY” Area: 180 m² Year Completion year of this architecture project Architects: Atelier Chen Hung Area Area of this architecture project Plummer & Smith Projects ShareFacebookTwitterPinterestWhatsappMailOrhttps://www.archdaily.com/933634/ocean-shores-house-atelier-chen-hung Clipboard CopyAbout this officeAtelier Chen HungOfficeFollow#TagsProjectsBuilt ProjectsSelected ProjectsResidential ArchitectureHousesOn FacebookOcean ShoresAustraliaPublished on February 13, 2020Cite: “Ocean Shores House / Atelier Chen Hung” 13 Feb 2020. ArchDaily. Accessed 10 Jun 2021.
Dakota men, women and youth rode into Mankato, Minn., on horseback on Dec. 26 to honor Dakota warriors hanged by Abraham Lincoln on that day in 1862 in the largest mass execution in U.S. history. The Dakota 38 + 2 Wokiksuye Sunk Akan Yankapi — the 17-day Dakota Prayer Ride and Water Walk — honors the 38 warriors hanged in Mankato, as well as two additional chiefs who were kidnapped from Canada three years later, brought back to the United States, and then executed. (tinyurl.com/yc7jvpt6)This year about 100 riders rode from their homes throughout South Dakota and elsewhere to gather at Sisseton, S.D., and began the honoring ride on Dec. 10. The ride follows the 330-mile path of their ancestors to the site of the mass hanging. Also this year Dakota runners started Dec. 25 from Fort Snelling in St. Paul, Minn., and joined the riders at Reconciliation Park in Mankato. Various riders addressed political and social struggles with messages on horse blankets and jackets. One horse wore a black blanket lettered, “Missing, Murdered Indigenous Women & Children.”Some participants in the Dakota 38 + 2 Wokiksuye Sunk Akan Yankapi — the Dakota Prayer Ride and Water Walk — ride into Mankato, Minn., near the end of their 17-day journey from South Dakota.Colonizing theft and murderDuring the westward drive of the U.S. to steal all Native nations’ lands and to murder the Indigenous peoples, U.S. troops were used in successive war campaigns. By 1860, just before the Civil War, the U.S. Army had six of its seven departments, comprising 183 companies, deployed west of the Mississippi River. This colonizing army was the principal institution of the settler state in the occupation and theft of the West. (Roxanne Dunbar-Ortiz, “An Indigenous Peoples’ History of the United States,” 2014)Lincoln, like every U.S. president before him, promised settlers land stolen from the Native nations in the West. During Lincoln’s presidential campaign, the “free-soilers,” who were opponents of slavery, demanded the government give them Indigenous land west of the Mississippi River. Following the secession of the southern states, Lincoln signed the Homestead Act, which resulted in the theft of over 270 million acres of Indigenous lands. Most of the stolen lands went to wealthy robber barons, for riches to be made from timber and mineral extraction — devastation of the environment for profits. The amount of land given to settlers for homesteads was a small portion of that total. Before and during the Civil War, poor whites who fought for the Confederacy were motivated by a similar desire to own stolen land and slaves — people stolen from their lands in Africa and sold to work the plantations.Broken treaties and mass executionFrom 1778 to 1871, the U.S. negotiated treaties with some 375 Native nations in its drive to militarily take over the West. The treaties itemized provisions of trade goods, cash payments, food and the right to live on some small pieces of their lands. These treaties, referenced in the U.S. Constitution, are the “law of the land.” But from the beginning the U.S. broke every treaty it signed. Minnesota, recognized as a state in 1858, created incentives to increase the number of colonizing settlers. In the fall of 1861, the Dakota Nation’s crops failed; then during a bitter winter they were snowed in and people starved. The treaties were broken, and food was not delivered. Traders rejected the tribe’s offer to buy food on credit at a meeting with Indian agents and traders. A Dakota spoke, “This is our reservation, and yet you go out and you cut our grass for your animals. You cut down our trees for your building and your fire. You shoot our game, which we have very little of anyway. It’s ours, you leave it alone.” (tinyurl.com/y8ykpyzo)The trader Andrew Myrick responded, saying the people could eat grass. By summer 1862, a portion of the Dakota rose up against the settler state in an attempt to drive the colonists out of the Minnesota River Valley. Myrick was later found with his mouth stuffed with grass. The Dakota War lasted two months before the Dakota surrendered; and the army marched the prisoners to Ft. Snelling to be executed. After 392 Dakota men were tried in English, with no recognition of sovereignty and treaty violations, they were all sentenced to death. (tinyurl.com/yb8uasbv)Lincoln ordered that 38 should be randomly selected to be hanged in Mankato. The army deployed 1,500 cavalry and soldiers at the hanging; retribution did not end there. The remains of the Dakota men were mutilated and pillaged. (tinyurl.com/yc7jvpt6)A ride to commemorate the warriors“When the 38+2 were hung, for them it was over, but the women and children endured terrible suffering,” said one of this year’s riders, Helena LaBatte. “The cavalry did what they wanted with them. They chose who they wanted, what age and what gender.”The Wokiksuye Commemorative Ride began in 2008, as a result of an earlier dream of Jim Miller, a Dakota elder from Cheyenne River Reservation and a Vietnam veteran. He dreamed that 38 Dakota would ride on horseback each year to honor the warriors hanged at Mankato after the Dakota Uprising.“This walk is about healing the women, and also for reconciling our men and women,” LaBatte continued. “Women were the keepers of the water, the dogs and the horses. For us to be whole again, we need all three.” (tinyurl.com/y7pz7v27)Paula Looking Horse, one of the Water Walkers, said the planning this year reflected thought of “all the streams and rivers that the walk would cross over and how contaminated many are from dairy farm operations as well as the 2017 bitumen (coal) spill that happened just west of the Sisseton Wahpeton reservation.” Looking Horse said, “As we walked the path along the Minnesota, we felt our ancestors’ presence all the way. … We prayed for the healing of the water.”She added, “This year we also raised awareness about the epidemic of missing and murdered indigenous men, women and children. All of these issues are connected. If you don’t respect the people, you can’t respect the land or the water.”The Dakota were exiled from Minnesota; repression scattered survivors from Saskatchewan, Canada, to Nebraska. On May 8, 2017, descendants of those exiled Dakota met for the first time at Fort Snelling for the Dakota Truth-Telling Gathering. Kate Beane, a Dakota historian who works for the Minnesota Historical Society, said claims that the fort was built to keep the Dakota and Ojibwe at peace are “not actually the way we view this history.”“This fort was put here to pave the way for European settlement,” she said. “It is a symbol of colonization, of imperialism, of years of unjust negotiations and dealings with our community. Two of our warriors were hanged right over here, outside of the round tower. … So sometimes if you hear 38 plus two, those were the two.” (tinyurl.com/ya95krl5)The Wokiksuye Ride reveals the genocidal history of the United States. From the beginning, the settler state was founded to steal all lands and resources from the original peoples of this continent. Manifest Destiny, the philosophy of the founders of the U.S., remains the principle of the ruling class: to steal everything for profits, whether by war or so-called peaceful means. To this day these lands are still being plundered and desecrated for profits — to the increasing threat to life on Earth.FacebookTwitterWhatsAppEmailPrintMoreShare thisFacebookTwitterWhatsAppEmailPrintMoreShare this
Previous articleXiaomi’s Latest Air Charging and G9 Vacuum Cleaner DebutNext articleGlobal Residential Air Purifier Market 2020-2024: Market Analysis, Drivers, Restraints, Opportunities, and Threats – Technavio Digital AIM Web Support Operating Profit Free Cash Flow Free Cash Flow (Non-IFRS) (1) (4) Takeda initiates a clinical phase 1/2 study in Japan of TAK-919, Moderna’s COVID-19 vaccine candidate -1.5% WhatsApp Core Operating Profit Revenue TAGS -7.2% vs. PRIOR YEAR 124.0 750-850 UnderlyingManagement Guidance 67.9 Reported EPS (Yen) 30.8% 3,200.0 79 Q3 FY2020 YTD Takeda FY2020 Q3 Results Demonstrate Growth Acceleration and Continued Resilience; Full-Year Management Guidance for FY2020 Confirmed, Forecast Raised for Free Cash Flow and Reported EPS -27 yen 434.0 vs. PRIOR YEAR 780.6 (3) -3.6% Reported Product RevenueJPY (billion) Annual Dividend per Share (Yen) 14.8% Twitter 434.0 Net Profit +0.7pp 319.3 CORE (Non-IFRS) (1) Low-single-digit growth 333 yen 180.5 +25.9% 32.1% Pinterest REPORTED ALUNBRIG -3.6% 700-800 610.0 115 yen 178.9 TAKHZYRO 248.0 (1)Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ (2)Underlying growth compares two periods (quarters or years) of financial results under a common basis and is used by management to assess the business. These financial results are calculated on a constant currency basis and excluding the impact of divestitures and other amounts that are unusual, non-recurring items or unrelated to our ongoing operations. (3)Core Operating Profit represents net profit adjusted to exclude income tax expenses, the share of profit or loss of investments accounted for using the equity method, finance expenses and income, other operating expenses and income, amortization and impairment losses on acquired intangible assets and other items unrelated to Takeda’s core operations, such as purchase accounting effects and transaction related costs. (4)Free Cash Flow represents cash flows from operating activities, excluding acquisition of plant, property and equipment, and including proceeds from sales of plant, property and equipment, as further adjusted to exclude the acquisition of intangible assets and the acquisition of investments, and to include the proceeds from sales and redemption of investments and proceeds from sales of business, net of cash and cash equivalents divested. FY2020 Q3 YTD RESULTS DEMONSTRATE TAKEDA’S CONTINUED RESILIENCE Reported revenue, at JPY 2,427.5 billion (~$23.5B), was impacted primarily by foreign exchange and divestitures, however Takeda delivered year-to-date underlying revenue growth of 1.1% in the third quarter of FY2020, which was driven by strong growth in ENTYVIO, TAKHZYRO, and Immunoglobulin, and was consistent with full year guidance of “low-single-digit growth.” Takeda delivered reported operating profit of JPY 358.7 billion (~$3.5B), which grew 120.7%, reflecting lower purchase price accounting (PPA) and integration costs. Core operating profit, which adjusts for PPA and non-recurring items, declined year-on-year to JPY 780.6 billion (~$7.6B) owing to foreign exchange impact and divestitures. The core operating profit margin was 32.2%. Underlying core operating profit grew 8.5% year-on-year. Underlying core operating profit margin, which adjusts for the impact of foreign exchange and divestiture effects, was 32.1%, driven by synergies and OPEX efficiencies. Takeda’s reported net profit was JPY 178.9 billion, a 320.8% increase compared with the same period in the prior year. Operating cash flow increased by 25.9% to JPY 610.0 billion, strengthening Takeda’s balance sheet and more than enabling the Company to satisfy dividend, debt, and interest payments. Free cash flow, which also reflects capital expenditures and proceeds from asset sales, was JPY 717.5 billion (~$7.0B). This represented a decrease of 3.8% in reported free cash flow versus the prior year; the growth rate was impacted by the ~JPY 375.5BN cash received in July 2019 for XIIDRA ®. Robust cash flow enabled further de-leveraging in Q3 and led to a 3.6x net debt/adjusted EBITDA ratio at the end of the period. The overall impact of the global spread of COVID-19 on Takeda’s consolidated financial results for the nine-month period ended December 31, 2020 was not material, with several offsetting factors. There were adverse effects due to COVID-19 observed in certain therapeutic areas, especially in Neuroscience during periods when stay-at-home restrictions were in place reducing patient visits to medical care providers. This trend has fluctuated throughout the nine-month period, especially in recent months, as transmission of COVID-19 has increased significantly in many parts of the world. These adverse impacts have been partially offset by benefits from prescribing trends during the pandemic, such as an expansion of certain products with a more convenient administration profile that was observed in the early phase of the outbreak. With regard to operating expenses, voluntary suspension of certain business activities such as business travel and events in response to COVID-19 led to lower spending. As a result of these factors, the impact on Takeda’s profit was immaterial. For the latest Takeda communications regarding COVID-19, please click here to visit the COVID-19 Information Center on Takeda’s website. COMMERCIAL UPDATES ACROSS FIVE KEY BUSINESS AREAS Takeda’s five key business areas — Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology and Neuroscience — with JPY 1,982.1 billion of reported revenue representing approximately 82% of total Q3 YTD revenues – delivered year-on-year underlying revenue growth of 4.4%. Takeda’s 14 global brands, with reported revenue of JPY 910.3 billion (~$8.8B) in aggregate, delivered a 15.4% increase in Q3 YTD underlying revenue growth compared to a year before. Gastroenterology The Gastroenterology franchise with JPY 588.8 billion in reported revenue represented 24% of sales, with underlying revenue growth of 14%. This was spearheaded by continued exceptional growth through expanded first line share of gut-selective ENTYVIO in the U.S., EU, and Japan. Rare Diseases The Rare Diseases franchise with JPY 446.7 billion in reported revenue represented 18% of sales, with underlying revenue growth declining 3%. The hereditary angioedema portfolio saw 16% underlying revenue growth, driven by continued excellent performance from TAKHZYRO, which continues to expand the hereditary angioedema prophylaxis market. Rare Hematology declined 11% on an underlying basis, with the competitive landscape in line with expectations. Rare Metabolic declined 1% on an underlying basis, but excluding NATPARA the portfolio saw 7% growth. Takeda is working closely with the U.S. Food and Drug Administration (FDA) on a proposed plan to resupply NATPARA in the U.S. and had announced earlier in FY2020 that the required device modifications and product testing will likely delay availability beyond FY2020. PDT Immunology PDT Immunology with JPY 313.0 billion in reported revenue represented 13% of sales, with underlying revenue growth of 9% driven by continued strong Gammagard-Liquid demand in the U.S. and subcutaneous IG worldwide. Albumin sales declined 10% versus prior year, partially due to phasing and supply dynamics in China in 2019 and in some part due to a temporary interruption in submitting batches of Albumin Glass for release in China in Q3, for which we expect a resolution soon. Oncology Oncology with JPY 318.5 billion in reported revenue represented 13% of sales, with underlying revenue growth of 3%. Takeda’s portfolio continues to expand indications as growth brands offset the decline of older products in the portfolio. Neuroscience Neuroscience with JPY 315.1 billion in reported revenue represented 13% of sales, declining 2% on an underlying basis. The portfolio experienced a slowdown in momentum attributable to COVID-19 stay-at-home restrictions that reduced patient visits and diagnoses. A recovery of prescribing trends has been noted, but new patient starts are not yet back to pre-COVID levels. Twitter +8.5% Product Business areas PDT Immunology -3.8% 2,427.5 Revenue +320.8% 65.9 (billion yen, exceptpercentages and pershare amounts) 420 +38.1% +4.5% +87 yen +8.3pp 519.8 2,427.5 NINLARO Immunoglobulin 717.5 358.7 3,200.0 Q3 FY2020 YTD +20.4% Pinterest Takeda licensed TAK-919 (Moderna) and TAK-019 (Novavax) COVID-19 vaccines in Japan, with approvals expected in FY2021 Press Release Oncology Press Release +13.7% ( Press Release ), ( Press Release ) FY2020 GUIDANCE Full-Year Management Guidance Confirmed; Reported EPS Upgrade on More Favorable Tax Rate Assumption and Increased Forecast for Free Cash Flow Reflecting Additional Sale of Securities Core Operating Profit Margin +120.7% Facebook Takeda has solid growth momentum heading into Q4 FY2020 and potential for accelerated underlying growth and achieving an underlying core operating profit margin in the mid-30s over the medium term. Core and underlying guidance for FY2020 remains unchanged. Key Assumptions in FY2020 Forecast Company guidance reflects management’s expectations for continued business momentum across Takeda’s five key business areas, underlying revenue growth of its 14 global brands, and accelerated realization of cost synergies. FY2020 guidance also reflects the following key assumptions, including (i) that there will not be an additional 505(b)2 competitor for subcutaneous VELCADE launched in the U.S. within FY2020; (ii) includes the impact of divestitures disclosed by Takeda as through February 4, 2021, with the exception of the divestment of Takeda Consumer Healthcare Company and non-core assets in China; and (iii) management’s current expectations regarding COVID-19. Based on currently available information, Takeda believes that its financial results for FY2020 will not be materially affected by COVID-19 and, accordingly, Takeda’s FY2020 forecast reflects this belief. However, the situation surrounding COVID-19 remains highly fluid, and future COVID-19-related developments in FY2020, including new or additional COVID-19 outbreaks and additional or extended lockdowns, shelter-in-place orders or other government action in major markets, could result in further or more serious disruptions to Takeda’s business, such as slowdowns in demand for Takeda’s products, supply chain related issues or significant delays in its clinical trial programs. These events, if they occur, could result in additional impacts on Takeda’s business, results of operations or financial condition, as well as resulting in significant deviations from Takeda’s FY2020 forecast. For more details on Takeda’s Q3 FY2020 results and other financial information, please visit: https://www.takeda.com/investors/reports/quarterly-announcements/ Further Information Takeda will share details regarding its commercial strategy in emerging markets and progress on its pipeline at its upcoming Growth & Emerging Markets Strategic Update call on March 11, 2021 and part 2 of its Wave 1 Pipeline Market Opportunity call on April 6, 2021, respectively. About Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited ( TOKYO: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com. Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Certain Non-IFRS Financial Measures This press release and materials distributed in connection with this press release include certain IFRS financial measures not presented in accordance with International Financial Reporting Standards (“IFRS”), such as Underlying Revenue, Core Operating Profit, Underlying Core Operating Profit, Core Net Profit, Underlying Core EPS, Net Debt, EBITDA, Adjusted EBITDA and Free Cash Flow. Takeda’s management evaluates results and makes operating and investment decisions using both IFRS and non-IFRS measures included in this press release. These non-IFRS measures exclude certain income, cost and cash flow items which are included in, or are calculated differently from, the most closely comparable measures presented in accordance with IFRS. By including these non-IFRS measures, management intends to provide investors with additional information to further analyze Takeda’s performance, core results and underlying trends. Takeda’s non-IFRS measures are not prepared in accordance with IFRS and such non-IFRS measures should be considered a supplement to, and not a substitute for, measures prepared in accordance with IFRS (which we sometimes refer to as “reported” measures). Investors are encouraged to review the reconciliation of non-IFRS financial measures to their most directly comparable IFRS measures. Further information on certain of Takeda’s Non-IFRS measures is posted on Takeda’s investor relations website at https://www.takeda.com/investors/reports/quarterly-announcements/ Medical information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Financial information Takeda’s financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”). The revenue of Shire plc (“Shire”), which was historically, presented by Shire in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”), has been conformed to IFRS, without material difference. Convenience translations of JPY figures into USD are included for reference and have been calculated at a rate of JPY/USD of 103.19. During FY2019, Takeda completed the purchase price allocation for the assets acquired and the liabilities assumed as part of the Shire acquisition. Accordingly, PL statements for FY2019 Q3 were retrospectively adjusted. i Please note the December 2020 debt profile assumes completion of ongoing make-whole calls on $1.25B 2021, $0.9B 2021 and $0.3B 2022 (completion scheduled for FY2020 Q4). View source version on businesswire.com:https://www.businesswire.com/news/home/20210203006048/en/ CONTACT: Media Contacts: Japanese Media Kazumi Kobayashi [email protected] +81 (0) 3-3278-2095 Media outside Japan: Holly Campbell [email protected] +1 480-213-8368 Investor Relations: Christopher O’Reilly [email protected] +81 (0) 3-3278-2543 KEYWORD: JAPAN ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2021. PUB: 02/04/2021 01:00 AM/DISC: 02/04/2021 01:01 AM http://www.businesswire.com/news/home/20210203006048/en ENTYVIO COST SAVINGS AND DIVESTITURES Synergy deliverables and operational efficiencies supported margin performance, as Takeda delivered a year-to-date underlying core operating profit margin of 32.1%. Takeda is also deleveraging rapidly, with a net debt/adjusted EBITDA ratio of 3.6x at the end of Q3 (December 31, 2020), down from 3.8x in March 2020, even after the full-year dividend payment. Gross debt principal has reduced JPY 1.3TN (~$12.5B) in two years since the quarter ending March 31, 2019 (close of the Shire acquisition was announced on January 8, 2019), and Takeda is on course to meet its medium-term deleveraging goal of 2x within FY2021-FY2023. i Takeda exceeded its $10B non-core asset divestiture target and has announced 11 deals since January 2019 to date for a total aggregate value of up to ~$11.6 billion, most recently including:The completion of the previously announced sale of a portfolio of select OTC and prescription products to Hypera S.A. for a total value of $825 million USD. ( Press Release )The completion of the previously announced sale of TachoSil ® Fibrin Sealant Patch to Corza Health, Inc. for €350 million. ( Press Release )The completion of the previously announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD. ( Press Release )The completion of the previously announced sale of a portfolio of select products to Celltrion Inc. for a total value of $278 million USD inclusive of milestone payments. ( Press Release )An agreement to divest a portfolio of non-core prescription pharmaceutical products sold in China to Hasten Biopharmaceutic Co., Ltd. for $322 million USD, subject to customary legal and regulatory closing conditions. ( Press Release ) Takeda further exceeded its original $700 million target and Q2 total of $1.1B for incremental cash from sales of real estate and securities, receiving ~$1.4B to date. As a result, the Company is raising its full year FY2020 Free Cash Flow forecast by JPY 50 billion to JPY 750 – 850 billion. PIPELINE UPDATE: R&D PROGRESS WITH SUBMISSION OF TAK-721, THE FIRST OF SEVEN POTENTIAL FILINGS IN THE NEXT 12 MONTHS Takeda has built a world-class, state of the art R&D engine and has generated a diverse and dynamic pipeline of approximately 40 clinical-stage new molecular entities (NMEs) that is beginning to deliver. The company’s Wave 1 pipeline NMEs, representing potential best-in-class/first-in-class therapies, has a number of notable anticipated near-term late-development milestones, pivotal data readouts or pivotal study starts. Takeda’s pipeline portfolio has the potential to contribute significantly to its growth over the next decade, and remains on track to deliver on its milestone goals. Since Q2, one of its twelve near-term pivotal milestones has already been met (Maribavir phase 3 data readout). This is also one of five pivotal data readouts expected through fiscal year 2022, with additional near-term development milestones expected across all Wave 1 programs. Takeda’s R&D engine continued to advance its Wave 1 pipeline, with recent highlights including:TAK-721 has been granted priority review from the FDA and remains on track to be the first FDA-approved agent to treat eosinophilic esophagitis. TAK-721 previously received both Breakthrough Therapy designation and Orphan Drug designation from the FDA. ( Press Release )TAK-003, Takeda’s tetravalent dengue vaccine candidate, continued to protect against dengue illness with an acceptable safety profile in the two years safety and efficacy follow-up published in The Journal of Infectious Diseases in December 2020. Regulatory submissions to the EMA and dengue endemic countries are expected in FY2020 Q4, containing three years of safety and efficacy follow-up; this data is to be presented at a medical meeting in FY2021.Mobocertinib (TAK-788), a potential new oral standard of care for NSCLC patients with EGFR Exon20 insertion mutations, demonstrated clinically meaningful and durable responses in data presented at the 2020 World Conference on Lung Cancer (WCLC), with a confirmed objective response rate of 35% as assessed by investigator and a median duration of response of 17.5 months. It remains on track for FDA submission in Q4 2020 for Platinum Pretreated Patients with EGFR Exon20 insertion mutations. ( Press release )Maribavir(TAK-620) met its phase 3 primary endpoint for the treatment of transplant recipients with refractory/resistant cytomegalovirus infections ( Press release ). Positive Phase 3 data for TAK-620 will be presented at the Transplantation & Cellular Therapy Meetings (TCT) on February 12 and the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting on March 14-17. Takeda anticipates FDA filing for maribavir as a treatment for CMV infection and disease in transplant patients resistant or refractory to prior therapy in H1 FY2021. Other Notable Updates In 2020, Takeda ranked first in NDA approvals in China, with four approvals including TAKHZYRO ( Press Release ), ENTYVIO, ADCETRIS, and REPLAGAL. At the virtual 62 nd American Society of Hematology (ASH) Annual Meeting & Exposition in December 2020, Takeda presented nine abstracts on key learnings from real-world data and retrospective studies. Takeda continues to gather and apply real-world evidence in the treatment of hemophilia, von Willebrand disease (VWD) and sickle cell disease (SCD) and advance personalized treatment in its ongoing commitment to people living with bleeding disorders. ( Press Release ) At the 2020 American College of Allergy, Asthma and Immunology (ACAAI) Virtual Annual Scientific Meeting, Takeda shared final results from the Phase 3 HELP Study™ Open-Label Extension that demonstrate TAKHZYRO (lanadelumab-flyo) injection as a potential long-term preventive treatment option in patients with Hereditary Angioedema. The results were also published in the November 2020 issue of ACAAI’s journal Annals of Allergy, Asthma & Immunology. ( Press Release ) Lastly, Takeda is excited about the recent regulatory progress of a number of transformative therapies, including the FDA approval for the Supplemental New Drug Application (sNDA) of ICLUSIG (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML. ( Press Release ) KEY CORPORATE INITIATIVES Several examples of corporate achievements in Q3 demonstrate Takeda’s progress toward its vision — “discover and deliver life-transforming treatments, guided by our commitment to Patients, our People and the Planet.” Patients: Takeda Demonstrates Industry Leadership in 2021 Access to Medicines Index Takeda was ranked sixth overall in the 2021 Access to Medicine (AtM) Index. A rigorous, biennial research project, the AtM Index combines data-collection, verification, scoring and analysis to compare 20 of the world’s largest pharmaceutical companies on their efforts to address access to medicines. The company achieved notable high scores in all three technical areas evaluated by the Index, including being ranked first in “Governance of Access”. Takeda also demonstrated strong performance in the areas of health strengthening and compliance. This ranking demonstrates Takeda’s values-driven strategy and how an ‘Access First’ approach across its Growth & Emerging Markets region is helping patients overcome access challenges in a more sustainable manner. ( Press Release ) People: Takeda Receives Global Top Employer Recognition Takeda was one of only 16 companies to be named as a global Top Employer ® for 2021, an accolade the company has now received for a fourth consecutive year. The Top Employers Institute provides annual award certification to companies with outstanding culture, work environments, benefits and opportunities for their people based on the results of its HR Best Practices Survey. Takeda excelled globally in the areas of Values, Ethics & Integrity, Organizational Change, Leadership, Sustainability, Performance Management and Engagement and was also certified as a Top Employer in four regions and 38 countries. This honor demonstrates Takeda’s continued commitment to creating an exceptional people experience for its global workforce. ( Press Release ) Planet: Takeda Achieves Carbon Neutral Goal Takeda recently announced it achieved carbon neutrality in its value chain for its fiscal year 2019. This milestone was met by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. Such actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2 and 3 emissions and represent a significant step forward in Takeda’s sustainability journey. Minimizing the environmental impact of its business is a critical priority for Takeda and at the heart of its purpose: achieving Better Health for People, Brighter Future for the World. ( Press Release ) Read more about how Takeda continues to deliver on its commitments to patients, people and the planet through its purpose-led sustainability commitment in its 2020 Sustainable Value Report: https://www.takeda.com/corporate-responsibility/sustainable-value-report/ COVID-19 UPDATE Guided by its values, Takeda’s response to COVID-19 has focused on protecting the health and safety of employees, striving to ensure its medicines are available to patients who rely on them and playing a part to reduce transmission and support the communities where its employees live and work. Takeda has also undertaken a number of efforts to help the world respond to COVID-19, most recently including: +24.0% Margin Reported Operating Profit 116 Gastroenterology Q3 YTD Global Brand Highlights OSAKA, Japan–(BUSINESS WIRE)–Feb 4, 2021– Takeda Pharmaceutical Company Limited ( TOKYO:4502/NYSE:TAK ) (“Takeda”) today announced financial results for the third quarter of fiscal year 2020 (period ended December 31, 2020). TAKEDA CHIEF FINANCIAL OFFICER COSTA SAROUKOS commented: “Our third-quarter results demonstrate the resilience of our business model and the depth of our portfolio, with strong growth generated by our 14 global brands. As a values-based and R&D driven biopharmaceutical company, we remain focused on bringing life-transforming treatments to people with high unmet needs around the world. With the first of our seven potential filings in the next 12 months complete, we look forward to delivering the next generation of potentially transformative medicines and maintaining our commitment to patients, our people and the planet. “While maintaining business momentum, we also continue to deliver on our financial commitments, realizing strong year-to-date margins and cash flow, and exceeding our target for non-core asset divestitures. This progress reflects our ability to effectively and efficiently integrate the operations of Takeda and Shire, as we capture synergies and focus investment in our key business areas. “Takeda’s strong financial performance in Q3 allows us to confirm management guidance for FY2020, with further growth acceleration expected in Q4 as we conclude the fiscal year. Reflecting on the transformation of Takeda over the past few years and the world-class R&D engine we have built, we look to 2021 as an important inflection point, filled with a number of pivotal milestones that will position us for long-term sustainable growth.” FINANCIAL AND BUSINESS HIGHLIGHTS Results for Q3 FY2020 YTD (Nine-Month Period Ended December 31, 2020) 984.0 Oncology Local NewsBusiness Core EPS (Yen) UNDERLYING (2) (Non-IFRS) (1) Low-30s% Reported Net Profit +1.1% FY2020 PRIOR FORECAST (October 2020) Rare Diseases 30.8% 984.0 High-single-digit growth World’s Leading Life Science Companies Now Enrolling COMMUNITY, A Global Platform Trial For Hospitalized Patients with COVID-19 420 +29.2% By Digital AIM Web Support – February 4, 2021 EPS (JPY) 6.5 FY2020 UPDATED FORECAST (February 2021) 180 Operating Cash Flow (billion yen) Year-over-Year UnderlyingRevenue Growth Facebook 180 32.2% WhatsApp Low-teen growth
Servicers Navigate the Post-Pandemic World 2 days ago Servicers Navigate the Post-Pandemic World 2 days ago Tagged with: Auction.com Nowcast Collingwood Group Existing Home Prices Existing Home Sales National Association of Realtors The Best Markets For Residential Property Investors 2 days ago Demand Propels Home Prices Upward 2 days ago The Best Markets For Residential Property Investors 2 days ago Data Provider Black Knight to Acquire Top of Mind 2 days ago Sign up for DS News Daily Existing home sales are projected to fall between seasonally adjusted annual rates of 5.15 and 5.47 million annually with a target of 5.31 million during April, according to Auction.com’s April 2015 Real Estate Nowcast released Wednesday.April’s target annual sales rate for existing homes of 5.31 million is an increase of 2.3 percent from March and 11.8 percent from April 2014, according to Auction.com.”Among the factors contributing to the jump in March’s existing home sales, pent-up demand from weak sales in January and February probably played a significant role,” Auction.com EVP Rick Sharga said. “Consumer psychology is likely also at play here: with talk of the Fed hiking interest rates as early as June, buyers who’ve been sitting on the sidelines may have decided to buy now and lock in today’s historically low interest rates.”Sharga also noted that while the 5.31 million target number for April is up both month-over-month and year-over-year, a truly healthy housing market would be on a pace for about six million in existing home sales annually. He said the annual rate of existing home sales will probably continue at about the five million range for the next year.Regarding the housing market this spring, Tim Rood, Chairman of the Washington, D.C.-based Collingwood Group and former Fannie Mae executive, told Dirk Van on Westwood One’s “Radio Light” program that the market “seems to be moving in the right direction. We were concerned coming in to this spring buying season that we were at a bit of an inflection point or tipping point. As we saw things continue to kind of lament and slow down than there was a great risk that we would fall back and have kind of an echo housing drop but it looks like we are still moving forward.” Click here to hear Van’s interview with Rood.April’s Auction.com Nowcast indicates that existing home prices will fall in the range of $201,052 to $222,215 for the month. The targeted price of $211,633 is up by 5 percent from April 2014. The release from Auction.com noted that the existing home sales data for March released Wednesday by the National Association of Realtors (NAR) found that both the annual rate of existing home sales for March (5.19 million) and the existing home price for March ($212,100) were within the ranges for March that Auction.com predicted a month ago in the Nowcast. The existing home price of $212,100 represented an increase of 7.8 percent from the previous March.”After a quiet start to the year, sales activity picked up greatly throughout the country in March,” NAR Chief Economist Lawrence Yun said. “The combination of low interest rates and the ongoing stability in the job market is improving buyer confidence and finally releasing some of the sizable pent-up demand that accumulated in recent years.”Recent improvements in the labor market could provide a solid foundation for further growth of the housing market, according to Auction.com Chief Economist Peter Muoio.”Despite some wobbles in recent macroeconomic indicators, we’ve seen indications of an improved U.S. labor market, suggesting a firmer foundation for growth,” Muoio said. “These indicators include not only headline employment growth and unemployment rates, but also the pace of voluntary quits, the stabilization of labor force participation and even some nascent signs of stirring wage growth. The improved labor market is an essential underlying footing for healthy home sales, and March’s results – and more broadly the green shoots of housing sales and price strength – appear to bear this out.”Auction.com’s Nowcast model uses industry data, proprietary company transactional data and Google search activity data to predict market trends as they are occurring, weeks in advance of the release of other benchmark studies. Related Articles Data Provider Black Knight to Acquire Top of Mind 2 days ago About Author: Brian Honea Auction.com Nowcast Collingwood Group Existing Home Prices Existing Home Sales National Association of Realtors 2015-04-22 Brian Honea Governmental Measures Target Expanded Access to Affordable Housing 2 days ago Brian Honea’s writing and editing career spans nearly two decades across many forms of media. He served as sports editor for two suburban newspaper chains in the DFW area and has freelanced for such publications as the Yahoo! Contributor Network, Dallas Home Improvement magazine, and the Dallas Morning News. He has written four non-fiction sports books, the latest of which, The Life of Coach Chuck Curtis, was published by the TCU Press in December 2014. A lifelong Texan, Brian received his master’s degree from Amberton University in Garland. Share Save Home / Daily Dose / Increases in Existing Sales and Prices Suggest Housing is Gaining Momentum in Spring Subscribe Previous: Treasury: Taxpayer Bailout of Fannie Mae and Freddie Mac Was Not an ‘Ordinary’ Loan Next: DS News Webcast: Thursday 04/23/2015 April 22, 2015 1,247 Views The Week Ahead: Nearing the Forbearance Exit 2 days ago Print This Post Increases in Existing Sales and Prices Suggest Housing is Gaining Momentum in Spring Demand Propels Home Prices Upward 2 days ago in Daily Dose, Featured, Market Studies, News Governmental Measures Target Expanded Access to Affordable Housing 2 days ago
The PSNI in Strabane are playing down claims of a lockdown on Sunday night last which led to police refusing to attend the scene of a burglary in Sion Mills.The claim’s been made by Cllr Patsy Kelly, who says a couple contacted police after their home was broken into on Sunday night to be told a detectiver would be there the next day.However, police say that was done with the agreement of the victims, who indicated they did not need an immediate police presence. WhatsApp By News Highland – March 18, 2015 Google+ Pinterest Google+ News 75 positive cases of Covid confirmed in North Further drop in people receiving PUP in Donegal Twitter Gardai continue to investigate Kilmacrennan fire Facebook RELATED ARTICLESMORE FROM AUTHOR 365 additional cases of Covid-19 in Republic Previous articleCouncil tenants names and addresses to be handed over to Irish WaterNext articleCo Donegal stargazers treated to spectacular Northern Lights display News Highland Main Evening News, Sport and Obituaries Tuesday May 25th Man arrested on suspicion of drugs and criminal property offences in Derry Police in Strabane play down claims of Sunday night lockdown Pinterest Facebook WhatsApp Twitter
Homepage BannerNews By News Highland – October 2, 2015 WhatsApp RELATED ARTICLESMORE FROM AUTHOR Main Evening News, Sport and Obituaries Tuesday May 25th WhatsApp Pinterest 75 positive cases of Covid confirmed in North 365 additional cases of Covid-19 in Republic Gardai continue to investigate Kilmacrennan fire Twitter Playwright Brian Friel has died at the age of 86 Brian Friel, one of Ireland’s greatest playwrights, has died at the age of 86.He passed away this morning.Brian Friel was born in Omagh, in 1929 but moved to Donegal in 1967 after becoming a teacher.He was educated in St Columb’s College, Derry as was poet Seamus Heaney and politician John Hume.’Dancing at Lughnasa’ which is believed to be based in Glenties, is regarded as his most successful play, winning three Tony Awards in 1992. Facebook Twitter Pinterest Facebook Previous articleCruciate injury could rule Darach O’Connor out for nine monthsNext articleAudio Update: Cllr. Seamus Ó Domhnaill backs Councillor James Pat McDaid in upcoming Convention News Highland Google+ Google+ Man arrested on suspicion of drugs and criminal property offences in Derry Further drop in people receiving PUP in Donegal
News Updates”If Display Of Affection Between LGBT Partners Isn’t Indecent, It Can’t Be Bogged Down By Majority Perception:” Allahabad High Court Reinstates LGBT Member In Service Sparsh Upadhyay9 Feb 2021 12:01 AMShare This – xThe Allahabad High Court last week quashed the order of the cancellation of the appointment of the petitioner (one Pramod Kumar Sharma) on account of a viral video of the petitioner. The Bench of Justice Sunita Agarwal noted that in the Counter Affidavit (filed by the officer who had passed the order of cancellation) sexual orientation of the petitioner was stated to be…Your free access to Live Law has expiredTo read the article, get a premium account.Your Subscription Supports Independent JournalismSubscription starts from ₹ 599+GST (For 6 Months)View PlansPremium account gives you:Unlimited access to Live Law Archives, Weekly/Monthly Digest, Exclusive Notifications, Comments.Reading experience of Ad Free Version, Petition Copies, Judgement/Order Copies.Subscribe NowAlready a subscriber?LoginThe Allahabad High Court last week quashed the order of the cancellation of the appointment of the petitioner (one Pramod Kumar Sharma) on account of a viral video of the petitioner. The Bench of Justice Sunita Agarwal noted that in the Counter Affidavit (filed by the officer who had passed the order of cancellation) sexual orientation of the petitioner was stated to be indulgence in untoward activity. Observing that it is completely in violation of the observations of the Apex Court in Navtej Singh Johar v. Union of India reported in (2018) 10 SCC 1, the Court directed the Commandant General of Home Guards, Head Quarters, U.P. Lucknow to take the petitioner back in service with immediate effect. The matter before the Court Vide order dated 11th June 2019 the appointment of the petitioner to the post of post of Home Guard was cancelled on account of some video of the petitioner which was made viral by someone. Noting that the Order is in violation of the Navtej Singh Johar ruling, the Court remarked, “The Apex Court in the said case has held that the sexual orientation of the person is his individual choice and any act of treating it as an offence would be interference in the right of the privacy of the person concerned.” Importantly, the Court said, “It was held that any display of affection amongst the members of the LGBT community towards their partners in the public, so long as it does not amount to indecency or has the potentiality to disturb public order cannot be bogged down by majority perception.” Regarding the order passed by District Commandant of Home Guards, Bulandshahar, the Court called it “vindictive in nature”. Thus, allowing the Writ Petition, the Court quashed the said Order. Lastly, the Court directed, “The respondent No.2 i.e. the Commandant General of Home Guards, Head Quarters, U.P. Lucknow is directed to take the petitioner back in service with immediate effect. The petitioner shall be entitled to all admissible dues and the honorarium shall be paid regularly as and when the same falls due.” Notable orders of other High Courts Underlining that the transgender communities are required to be accorded equal status as the other prevalent genders of society, the Calcutta High Court last week issued direction that reservation and other benefits for transgenders in Joint CSIR-UGC NET Examinations at all levels be provided immediately. Recently, the Bihar Government informed the Patna High Court that vide notification dated 14th January, 2021, it has taken a decision for providing reservation in appointment to the post of Constables/Sub-Inspectors, for the persons belonging to the Transgender Community. Further, while noting that Transgender Persons (Protection of Rights) Act, 2019 permits a transgender person to have a right to be recognized and such transgender is permitted to have a right to self-perceived gender identity, the Bombay High Court (Aurangabad Bench) on Saturday (02nd January) allowed a transgender to contest village panchayat polls as a Woman candidate. The Bench of Justice Ravindra Ghuge allowed the plea filed by Anjali Guru Sanjana Jaan, who challenged an order passed by the returning officer who rejected her nomination for the village panchayat polls. Also, the Centre has recently informed the Delhi High Court that Transgender shall now be included as a separate gender category in Prison Statistics Report prepared by the National Crime Records Bureau (NCRB). The Kerala High Court has also observed that “Person cannot be denied a legitimate right only because she is a transgender”. Justice Devan Ramachandran noted this, while hearing a plea filed by a Transwoman, challenging Section 6 of the National Cadet Corps Act, 1948 as illegal and ultra vires of Articles 14, 15 and 21 of the Constitution of India. It may be noted that a Petition has been moved in the Kerala High Court challenging Section 6 of the National Cadet Corps Act, 1948 as illegal and ultra vires of Articles 14, 15 and 21 of the Constitution to the extent that it excludes the transgender community from enrolment with the National Cadet Corps. Notably, the High Courts of Karnataka, Jharkhand and Telangana have also ordered the Government to ensure that the Transgender community is provided adequate protection and benefits during the lockdown. In the month of May, a petition was also filed in the Kerala High Court seeking protection of the community against discrimination in the grant of relief measures during the lockdown. In the month of June, the Bombay High Court had directed the Principal Secretary to the State Social Justice and Special Assistance Department to consider and dispose of within a fortnight, concerns expressed by an activist working for the transgender community, regarding the plight of the members especially after the lockdown and seeking directions for the formulation of a welfare scheme for the 40,000 members of the community in the State. Recently, the Karnataka High Court has directed the State Government to take steps for implementation of the relevant provisions of the Transgender Persons (Protection of Rights) Act, 2019 and also extend all kinds of the reservation to members of the community. In the month of July, the Karnataka High Court had sought a reply from the state government on why it has not included a separate category for the transgender community in its notification for recruitment to the post of Special Reserve Constable Force and Bandsmen. Case title – Pramod Kumar Sharma v. State Of U P And 2 Others [WRIT – A No. – 8399 of 2020] Click Here To Download OrderRead OrderNext Story